My Cart
You have no items in your shopping cart.
Background
The human KCNA3 gene encodes the pore-forming subunit of Kv1.3, a voltage-gated potassium channel. Upregulation of Kv1.3 channels contributes to the activation of T-lymphocytes during inflammatory reactions; Kv1.3 channels are therapeutic targets in multiple sclerosis, cancer, obesity, diabetes, asthma, and autoimmune diseases.
| General Info | |
| Product Description | Human Kv1.3 potassium ion channel-expressing, stable replicating cell line (CHO). |
|---|---|
| Target Type | Ion Channel |
| Product Type | Replicating Cell Line |
| Family | Potassium, Voltage-Gated |
| Sub-Type | Kv1.3 |
| Class | Voltage-gated potassium channel |
| Therapeutic Area | cancer, metabolic & gastrointestinal, neurodegeneration & stroke, pain & inflammation, pulmonary-respiratory, vascular |
| Related Services | Large-scale Cryopreservation |
| Gene Name | KCNA3 |
| Validated Assay/Platform | IonWorks Quattro™ |
| References | Gutman GA, et al. 2005. Pharmacol Rev. 57:473-508. International Union of Pharmacology. LIII. Nomenclature and molecular relationships of voltage-gated potassium channels. |
| Host cell | CHO-K1 |
| Mycoplasma Status | Negative (MycoAlert Kit) |
| Growth media | DMEM/Ham's F12; 10% FBS; 500 µg/mL G418 |
| Storage & Packaging | |
| Packaging | Cryopreserved cells, 1-2x106 cells |
| Storage Recommendation | liquid nitrogen |
| Quantity | 1-2 million cells |
| Product Documentation | |
| Specification Sheet |  Download PDF Document |
